# Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

> **NCT00052403** · PHASE1 · WITHDRAWN · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** monoclonal antibody anti-anb3 integrin
- **PROCEDURE:** anti-cytokine therapy
- **PROCEDURE:** antiangiogenesis therapy
- **PROCEDURE:** antibody therapy
- **PROCEDURE:** biological response modifier therapy
- **PROCEDURE:** growth factor antagonist therapy
- **PROCEDURE:** monoclonal antibody therapy

## Key facts

- **NCT ID:** NCT00052403
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was not successful at recruiting particpants
- **Last updated:** 2014-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052403, "Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00052403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*